Pivotal Phase 3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) has begun Seasonal flu vaccine candidate (mRNA-1010) successfully boosted hemagglutination inhibition (HAI) ...

Investor interest in the biotechnology industry hit a fever pitch in 2021 around the time Moderna launched Spikevax, its COVID-19 vaccine. The company's sales surged to $18.5 billion in 2021 from ...

Former COVID-vaccine darling announces job cuts a day before quarterly results are set for release. The stock has tumbled more than 70% in the past year as losses have mounted. In a note to employees ...

Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...

Dec 4 (Reuters) - Moderna Inc (MRNA.O), opens new tab will be able to produce 500 million doses of its COVID-19 vaccine in 2021, Chief Executive Officer Stéphane Bancel said on Friday. The company has ...

Five years ago, Moderna, Inc. (MRNA) and Novavax, Inc. (NVAX) were two of the most talked about stocks across platforms like Seeking Alpha, social media, and likely in the national press of most ...

The Africa CDC responded to Moderna’s plans to step back from building a mRNA vaccine manufacturing facility in Kenya, saying the move by the Spikevax maker only "perpetuates" the inadequate response ...

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines ...